Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F–Fluorodeoxyglucose (18F–FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study

Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F–Fluorodeoxyglucose (18F–FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study

Abstract Background Tyrosine kinase inhibitors are the first line standard of care for treatment of metastatic renal cell carcinoma (RCC). Accurate response assessment in the setting of antiangiogenic therapies remains suboptimal as standard size-related response criteria do not necessarily accurate...

Full description

Bibliographic Details
Main Authors: Christian Kelly-Morland, Sarah Rudman, Paul Nathan, Susan Mallett, Giovanni Montana, Gary Cook, Vicky Goh
Format: Article
Language:English
Published: BMC 2017-06-01
Series:BMC Cancer
Subjects:
Metastatic renal cell carcinoma
Magnetic resonance imaging
Positron emission tomography
Pet/MRI
Response assessment
Online Access:http://link.springer.com/article/10.1186/s12885-017-3371-9

Internet

http://link.springer.com/article/10.1186/s12885-017-3371-9

Similar Items